<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metyrosine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metyrosine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Metyrosine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12185" href="/d/html/12185.html" rel="external">see "Metyrosine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F196116"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Demser</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F196129"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Tyrosine Hydroxylase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F196119"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="678d411f-b3ca-40d9-8568-e75b9195bd73">Pheochromocytoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pheochromocytoma:</b>
<b>Oral:</b> Initial: 250 mg 4 times/day, increased by 250 to 500 mg/day up to 4 g/day in 4 divided doses; titrate hypertensive patients to achieve normal blood pressure and symptom control and titrate normotensive patients to reduce catecholamines by ≥50%. Usual maintenance: 2 to 3 g/day in 4 divided doses; for preoperative preparation, administer optimum effective dosage for 5 to 7 days. <b>Note:</b> May be given in conjunction with an alpha-adrenergic antagonist (eg, phenoxybenzamine) to increase intraoperative hemodynamic stability; however, consider limiting dose of metyrosine to 2 g/day due to greater potential for intraoperative hemodynamic instability with higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28803996','lexi-content-ref-26362800','lexi-content-ref-26374407']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28803996','lexi-content-ref-26362800','lexi-content-ref-26374407'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991844"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989137"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F196120"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F196125"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years: Refer to adult dosing.</p></div>
<div class="block dorp drugH1Div" id="F51130104"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51130105"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F196099"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Extrapyramidal reaction (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (10%)</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Anxiety, confusion, depression, disorientation, hallucination, headache, overstimulation (after withdrawal), Parkinson’s disease, sedation</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Galactorrhea</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal pain, nausea, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Breast swelling, crystalluria, dysuria, ejaculatory disorder, hematuria, impotence</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Anemia, eosinophilia, thrombocythemia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Increased serum AST</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Nasal congestion, pharyngeal edema</p></div>
<div class="block coi drugH1Div" id="F196110"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to metyrosine or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F196096"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Crystalluria: May cause crystalluria; to minimize risk, maintain adequate hydration to achieve urine output ≥2L especially with doses &gt;2 g/day. Reduce dose or discontinue use if crystalluria occurs.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Appropriate use: Maintain fluid volume during and after surgery to avoid hypotension and maintain adequate perfusion. Metyrosine does not eliminate the danger of hypertensive crises or arrhythmias during surgery; blood pressure and electrocardiogram should be continuously monitored.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Long-term use: Safety of long-term use is not established; periodic evaluation of patient is recommended.</p></div>
<div class="block foc drugH1Div" id="F196106"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Demser: 250 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block geq drugH1Div" id="F196092"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323398"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Demser Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $549.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (metyroSINE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $437.57</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F13853024"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer without regard to meals.</p></div>
<div class="block admp drugH1Div" id="F52613324"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to meals.</p></div>
<div class="block use drugH1Div" id="F196107"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Pheochromocytoma: </b>Short-term management of pheochromocytoma before surgery; long-term management of pheochromocytoma when surgery is contraindicated or when chronic malignant pheochromocytoma exists</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> In general, metyrosine is reserved for patients who cannot be treated with combined alpha- and beta-adrenergic blockade due to intolerance or cardiopulmonary reasons (Butz 2017).</p></div>
<div class="block mst drugH1Div" id="F196133"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MetyroSINE may be confused with metyraPONE</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299707"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F196101"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: MetyroSINE may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: MetyroSINE may enhance the adverse/toxic effect of Bromopride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the sedative effect of MetyroSINE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: MetyroSINE may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer metyrosine until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: MetyroSINE may enhance the adverse/toxic effect of Metoclopramide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promethazine: MetyroSINE may enhance the adverse/toxic effect of Promethazine. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors: MetyroSINE may enhance the adverse/toxic effect of Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13841163"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block brc drugH1Div" id="F20616324"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if metyrosine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering metyrosine to nursing women.</p></div>
<div class="block mop drugH1Div" id="F13853026"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor blood pressure and electrocardiogram during surgery; routine urinalysis (urine output ≥2000 mL recommended especially with doses &gt;2 g/day)</p></div>
<div class="block pha drugH1Div" id="F196095"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks the rate-limiting step in the biosynthetic pathway of catecholamines. It is a tyrosine hydroxylase inhibitor, blocking the conversion of tyrosine to dihydroxyphenylalanine. This inhibition results in decreased levels of endogenous catecholamines. Catecholamine biosynthesis is reduced by 35% to 80% in patients treated with metyrosine at recommended doses.</p></div>
<div class="block phk drugH1Div" id="F196109"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~3-4 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily urine (53% to 88% as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58194322"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Demser</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Demser</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Demser | Metyrosine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Demser</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-28803996">
<a name="28803996"></a>Butz JJ, Weingarten TN, Cavalcante AN, et al. Perioperative hemodynamics and outcomes of patients on metyrosine undergoing resection of pheochromocytoma or paraganglioma. <i>Int J Surg</i>. 2017;46:1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrosine-drug-information/abstract-text/28803996/pubmed" id="28803996" target="_blank">28803996</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Demser (metyrosine) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15380719">
<a name="15380719"></a>Humphries D, Ruterbories K, Chan C, Narayanan R. Development and validation of a liquid chromatography-tandem mass spectrometric method for the determination of alpha-methyltyrosine in human plasma. <i>J Chromatogr B Analyt Tecnol Biomed Life Sci.</i> 2004;810(2):229-234.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrosine-drug-information/abstract-text/15380719/pubmed" id="15380719" target="_blank">15380719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26362800">
<a name="26362800"></a>Thanapaalasingham K, Pollmann AS, Schelew B. Failure of metyrosine therapy for preoperative management of pheochromocytoma: a case report. <i>Can J Anaesth</i>. 2015;62(12):1303-1307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrosine-drug-information/abstract-text/26362800/pubmed" id="26362800" target="_blank">26362800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26374407">
<a name="26374407"></a>Wachtel H, Kennedy EH, Zaheer S, et al. Preoperative metyrosine improves cardiovascular outcomes for patients undergoing surgery for pheochromocytoma and paraganglioma. <i>Ann Surg Oncol</i>. 2015;22(suppl 3):S646-S654.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrosine-drug-information/abstract-text/26374407/pubmed" id="26374407" target="_blank">26374407</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9647 Version 150.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
